参麦注射液联合贝那普利治疗慢性阻塞性肺疾病合并慢性肺源性心脏病临床效果研究

目的观察参麦注射液联合贝那普利治疗慢性阻塞性肺疾病(COPD)合并慢性肺源性心脏病(CPHD)的临床效果。 方法选取2016年1月至2017年10月河南省人民医院收治的79例COPD合并CPHD患者，按随机数表法分为A、B两组。A组患者在常规治疗的基础上服用贝那普利，B组在A组治疗的基础上接受参麦注射液辅助治疗。对比两组患者治疗前后LVEF、CO和FEV₁、FVC%水平，统计两组患者治疗总有效率和不良反应发生率。 结果B组患者治疗后LVEF、CO水平和FEV₁、FVC%水平均高于A组(P<0.05)；B组患者治疗总有效率(97.50%)高于A组(84.62%)，差异有统计学意义(P<0.05)；两组患者均未发生明显不良反应。 结论参麦注射液联合贝纳利普治疗COPD合并CPHD临床疗效较好，可有效改善患者心肺功能，具有临床推广价值。

Clinical effect of shenmai injection combined with benazepril in the treatment of chronic obstructive pulmonary disease combined with chronic pulmonary heart disease

ObjectiveTo observe the clinical effect of shenmai injection combined with benazepril in the treatment of chronic obstructive pulmonary disease (COPD) combined with chronic pulmonary heart disease (CPHD). MethodsSeventy-nine patients with COPD combined with CPHD admitted to Henan Provincial People's Hospital from January of 2016 to October of 2017 were randomly divided into two groups. Patients in group A were treated with benazepril on the basis of conventional treatment, while patients in group B were treated with ginseng injection on the basis of the treatment of group A. The levels of LVEF, CO, FEV₁ and FVC% before and after treatment were compared between the two groups, and the total effective rate of the two groups was statistically calculated. ResultsAfter treatment, LVEF, CO, FEV₁ and FVC% in group B were higher than those in group A (P<0.05). The total therapeutic efficiency of group B (97.50%) was higher than group A (84.62%), and the difference was statistically significant (P<0.05). No adverse reaction was observed in both groups. ConclusionShenmai injection combined with benazepril has a better clinical efficacy in the treatment of COPD with CPHD, can effectively improve the cardiopulmonary function of patients, deserves the clinical expansion.